Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 304

1.

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D, Decaudin C, Armand M, Della-Valle V, Diop MK, Ghamlouch H, Ropars V, Hérate C, Lara D, Durot E, Haddad R, Mylonas E, Damm F, Pflumio F, Stoilova B, Metzner M, Elemento O, Dessen P, Camara-Clayette V, Cosset FL, Verhoeyen E, Leblond V, Ribrag V, Cornillet-Lefebvre P, Rameau P, Azar N, Charlotte F, Morel P, Charbonnier JB, Vyas P, Mercher T, Aoufouchi S, Droin N, Guillouf C, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2019 Apr 24. doi: 10.1158/2159-8290.CD-18-0873. [Epub ahead of print]

PMID:
31018969
2.

Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.

Bahekar R, Dave B, Soman S, Patel D, Chopade R, Funde R, Kumar J, Sachchidanand S, Giri P, Chatterjee A, Mahapatra J, Vyas P, Ghoshdastidar K, Bandyopadhyay D, Desai RC.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1313-1319. doi: 10.1016/j.bmcl.2019.04.007. Epub 2019 Apr 4.

PMID:
30975623
3.

Characterization of transgenic mouse lines for labeling type I and type II afferent neurons in the cochlea.

Vyas P, Wu JS, Jimenez A, Glowatzki E, Fuchs PA.

Sci Rep. 2019 Apr 3;9(1):5549. doi: 10.1038/s41598-019-41770-5.

4.

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z.

5.

Inclusion of non-target antigen in vaccination favors generation of OVA specific CD4 memory T cells.

MohanKrishnan A, Patel H, Bhurani V, Parmar R, Yadav N, Dave N, Rana S, Gupta S, Madariya J, Vyas P, Dalai SK.

Cell Immunol. 2019 Mar;337:1-14. doi: 10.1016/j.cellimm.2018.11.005. Epub 2018 Nov 19.

PMID:
30773218
6.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
7.

SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells.

Chagraoui H, Kristiansen MS, Ruiz JP, Serra-Barros A, Richter J, Hall-Ponselé E, Gray N, Waithe D, Clark K, Hublitz P, Repapi E, Otto G, Sopp P, Taylor S, Thongjuea S, Vyas P, Porcher C.

Nat Commun. 2018 Dec 18;9(1):5375. doi: 10.1038/s41467-018-07787-6.

8.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

9.

Understanding Spatial and Contextual Factors Influencing Intraregional Differences in Child Vaccination Coverage in Bangladesh.

Vyas P, Kim D, Adams A.

Asia Pac J Public Health. 2019 Jan;31(1):51-60. doi: 10.1177/1010539518813604. Epub 2018 Nov 30.

PMID:
30499306
10.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.

11.

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Erratum in: Blood Cancer J. 2019 Feb 28;9(3):28.

12.

New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins.

Golovenko D, Bräuning B, Vyas P, Haran TE, Rozenberg H, Shakked Z.

Structure. 2018 Sep 4;26(9):1237-1250.e6. doi: 10.1016/j.str.2018.06.006. Epub 2018 Jul 26.

PMID:
30057026
13.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P.

Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16.

PMID:
30013198
14.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

15.

Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.

Tunstall O, Bhatnagar N, James B, Norton A, O'Marcaigh AS, Watts T, Greenough A, Vyas P, Roberts I, Wright M; British Society for Haematology.

Br J Haematol. 2018 Jul;182(2):200-211. doi: 10.1111/bjh.15390. Epub 2018 Jun 19. No abstract available.

PMID:
29916557
16.

Voltage-Gated Calcium Influx Modifies Cholinergic Inhibition of Inner Hair Cells in the Immature Rat Cochlea.

Zachary S, Nowak N, Vyas P, Bonanni L, Fuchs PA.

J Neurosci. 2018 Jun 20;38(25):5677-5687. doi: 10.1523/JNEUROSCI.0230-18.2018. Epub 2018 May 22.

17.

Cross fused renal ectopia with associated renal cell carcinoma.

Vyas P, Campbell K, Blute M.

Urol Case Rep. 2018 Mar 1;18:70-72. doi: 10.1016/j.eucr.2018.02.014. eCollection 2018 May. No abstract available.

18.

Assessment of different pretreatment technologies for efficient bioconversion of lignocellulose to ethanol.

Singh JK, Vyas P, Dubey A, Upadhyaya CP, Kothari R, Tyagi VV, Kumar A.

Front Biosci (Schol Ed). 2018 Jun 1;10:350-371. Review.

PMID:
29772563
19.

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.

Jakobsen NA, Vyas P.

Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s47-s53. doi: 10.7861/clinmedicine.18-2-s47.

20.

Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease.

Schlotter F, Halu A, Goto S, Blaser MC, Body SC, Lee LH, Higashi H, DeLaughter DM, Hutcheson JD, Vyas P, Pham T, Rogers MA, Sharma A, Seidman CE, Loscalzo J, Seidman JG, Aikawa M, Singh SA, Aikawa E.

Circulation. 2018 Jul 24;138(4):377-393. doi: 10.1161/CIRCULATIONAHA.117.032291.

PMID:
29588317

Supplemental Content

Loading ...
Support Center